Noxopharm patent applications relate to the form in which any isoflavonoid drug appears in the blood after rectal administration. These are not composition of matter patents relating to a particular molecule.
All lapsed or existing NRT/MEIP patents are irrelevant. The use of a suppository as cited in those patents also is irrelevant (a) because that was never reduced to practice, and (b) the production of the pro-drug form (idronoxil-C) is the critical bit of IP. Without that pro-drug form, the drug would not work.
This is patent 101 for anyone purporting to be an expert.
NOX announced on 10 April 2017 that it had filed a patent application for Idronoxil-C, a novel form of Idronoxil. This application has not yet entered the public domain, so any suggestion that NOX will not get patent protection for Idronoxil-C is based on ignorance.
Add to My Watchlist
What is My Watchlist?
